Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07252232 · ClinicalTrials.gov registry record · Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 7
- Study locations
NCT07252232: Recruiting Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
NCT07252232 is a Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 500 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07252232, a Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Primary Outcome
DFS defined as the time from randomization until disease recurrence or death from any cause, whichever occurs first. Recurrence is per response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by Investigator.
Conditions Studied
Interventions
- DRUG daraxonrasib
Study Locations (7)
Connecticut
- Hartford Healthcare - Hartford
Indiana
- Community Health Network - Indianapolis
Missouri
- Saint Luke's Cancer Institute - Kansas City
Ohio
- Taylor Cancer Research Center - Maumee
South Dakota
- Avera Cancer Institute - Sioux Falls
Virginia
- Virginia Cancer Specialists - Fairfax
Puerto Rico
- Pan American Oncology Trials, LLC - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2030-07-10 |
| Phase | Phase 3 |
What NCT07252232 shows while recruiting
NCT07252232 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher).
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which daraxonrasib is the first listed.
NCT07252232 lists 7 locations in 7 states (Connecticut, Indiana, Missouri).
Frequently Asked Questions
What is clinical trial NCT07252232 about?
NCT07252232 is a clinical study titled "Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)". The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
What is the current status of trial NCT07252232?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-12-15. Estimated completion is 2030-07-10.
What conditions does trial NCT07252232 study?
This clinical trial studies the following conditions: Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT07252232?
The interventions under investigation include: daraxonrasib (DRUG).
Who is sponsoring clinical trial NCT07252232?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07252232 being conducted?
This trial has 7 study locations across Connecticut, Indiana, Missouri, Ohio, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07252232's enrollment target sits among peer trials
500 30th of 278 higher than 247 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
-
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI